Factors Associated with Toxicity, Final Dose, and Efficacy of Methotrexate in Patients with Rheumatoid Arthritis

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2003 Apr 16

PMID 12695153

Citations 69

Authors

M Hoekstra

A E van Ede

C J Haagsma

M A F J Van de Laar

T W J Huizinga

M W M Kruijsen

R F J M Laan

Affiliations

Soon will be listed here.

Abstract

Objective: To study factors associated with toxicity, final dose, and efficacy of methotrexate (MTX) in patients with rheumatoid arthritis (RA).

Methods: Data were used from a randomised clinical 48 week trial on 411 patients with RA all treated with MTX, comparing folates and placebo. Logistic regression was used to study the relation between baseline variables and various dependent factors, including hepatotoxicity (alanine aminotransferase >/=3 x upper limit of normal), MTX withdrawal, final MTX dose >/=15 mg/week, and MTX efficacy.

Results: Addition of folates to MTX treatment was strongly related to the lack of hepatotoxicity. Next to this, high body mass index was related to the occurrence of hepatotoxicity. Prior gastrointestinal (GI) events and younger age were related to the adverse event, diarrhoea. Hepatotoxicity and GI adverse events were the main reason for MTX withdrawal, which in turn was associated with the absence of folate supplementation, body mass index, prior GI events, and female sex. Renal function (creatinine clearance >/=50 ml/min) was not associated with toxicity. Reaching a final dose of MTX of >/=15 mg/week was related to folate supplementation and the absence of prior GI events. Efficacy of MTX treatment was associated with low disease activity at baseline, male sex, use of non-steroidal anti-inflammatory drugs (NSAIDs), and lower creatinine clearance.

Conclusions: MTX toxicity, final dose, and efficacy are influenced by folate supplementation. Baseline characteristics predicting the outcome of MTX treatment are mainly prior GI events, body mass index, sex, use of NSAIDs, and creatinine clearance.

Citing Articles

Fatal Neutropenia Sepsis Following Acute Methotrexate Toxicity.

Jesiah N, Siva Y, Kt S Cureus. 2025; 17(1):e77754.

PMID: 39981473 PMC: 11840445. DOI: 10.7759/cureus.77754.

Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.

Mueller K, Saavedra A, OKeeffe L, Sparks J Drugs Aging. 2025; 42(2):81-94.

PMID: 39800810 DOI: 10.1007/s40266-024-01175-0.

Fibroblast-like synoviocyte targeting antibodies are associated with failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis.

Vandormael P, Fadlallah S, Ruytinx P, Pues A, Sleurs E, Liesenborgs J RMD Open. 2024; 10(4).

PMID: 39551578 PMC: 11574395. DOI: 10.1136/rmdopen-2024-004743.

Impact of MTHFR gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients.

Mutlak Q, Kasim A Sci Rep. 2024; 14(1):15119.

PMID: 38956106 PMC: 11219777. DOI: 10.1038/s41598-024-65199-7.

Graphene oxide quantum dots-loaded sinomenine hydrochloride nanocomplexes for effective treatment of rheumatoid arthritis via inducing macrophage repolarization and arresting abnormal proliferation of fibroblast-like synoviocytes.

Lin Y, Tang Y, Yi O, Zhu J, Su Z, Li G J Nanobiotechnology. 2024; 22(1):383.

PMID: 38951875 PMC: 11218134. DOI: 10.1186/s12951-024-02645-8.

References

Golden M, Katz R, Balk R, Golden H . The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol. 1995; 22(6):1043-7. View

Morgan S, Baggott J, Vaughn W, Austin J, Veitch T, Lee J . Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994; 121(11):833-41. DOI: 10.7326/0003-4819-121-11-199412010-00002. View

Gutierrez-Urena S, Molina J, Garcia C, Cuellar M, Espinoza L . Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996; 39(2):272-6. DOI: 10.1002/art.1780390214. View

Bologna C, Viu P, Jorgensen C, Sany J . Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol. 1996; 35(5):453-7. DOI: 10.1093/rheumatology/35.5.453. View

Bologna C, Viu P, Picot M, Jorgensen C, Sany J . Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol. 1997; 36(5):535-40. DOI: 10.1093/rheumatology/36.5.535. View

Alarcon G, Kremer J, Macaluso M, Weinblatt M, Cannon G, Palmer W . Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997; 127(5):356-64. DOI: 10.7326/0003-4819-127-5-199709010-00003. View

Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M . Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1998; 24(12):2299-303. View

Weinblatt M, Maier A, Fraser P, Coblyn J . Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol. 1998; 25(2):238-42. View

Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y . Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol. 1999; 28(5):273-81. DOI: 10.1080/03009749950155454. View

10.

Anderson J, Wells G, Verhoeven A, Felson D . Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000; 43(1):22-9. DOI: 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9. View

11.

van Ede A, Laan R, Rood M, Huizinga T, van de Laar M, van Denderen C . Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001; 44(7):1515-24. DOI: 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7. View

12.

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

13.

Carson C, Cannon G, Egger M, WARD J, Clegg D . Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum. 1987; 16(3):186-95. DOI: 10.1016/0049-0172(87)90021-7. View

14.

Hanrahan P, Russell A . Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol. 1988; 15(7):1078-80. View

15.

Kremer J, Lee R, Tolman K . Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum. 1989; 32(2):121-7. DOI: 10.1002/anr.1780320202. View

16.

Furst D, Koehnke R, Burmeister L, Kohler J, Cargill I . Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol. 1989; 16(3):313-20. View

17.

Alarcon G, Tracy I, Blackburn Jr W . Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 1989; 32(6):671-6. DOI: 10.1002/anr.1780320603. View

18.

Wernick R, Smith D . Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum. 1989; 32(6):770-5. DOI: 10.1002/anr.1780320616. View

19.

Brick J, Moreland L, Al-Kawas F, Chang W, Layne R, DiBartolomeo A . Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin Arthritis Rheum. 1989; 19(1):31-44. DOI: 10.1016/0049-0172(89)90085-1. View

20.

Cush J, Lipsky P, Postlethwaite A, Schrohenloher R, Saway A, Koopman W . Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum. 1990; 33(1):19-28. DOI: 10.1002/art.1780330103. View